

CSF SUSTAINED RELEASE PHARMACEUTICAL

Patent Number: JP62230729
Publication date: 1987-10-09
Inventor(s): FUJIOKA TAKAHARU; others: 02
Applicant(s): SUMITOMO PHARMACEUT CO
Requested Patent: ☐ JP62230729
Application: JP19860185437 19860806
Priority Number(s):
IPC Classification: A61K37/04
EC Classification:
Equivalents: JP1999987C, JP7025688B

Abstract

PURPOSE: A CSF sustained release pharmaceutical, obtained by containing a colony stimulating factor (CSF) in a specific carrier, e.g. collagen, gelatin, etc., useful for recovering granulocytopenia in leukocytes, cancer, etc., and capable of sustaining release for a long period.

CONSTITUTION: A CSF sustained release pharmaceutical obtained by blending, e.g. an aqueous solution of a colony stimulating factor (CSF) with an aqueous solution of a carrier, capable of in vivo administration and consisting of a low toxic compound, preferably collagen, gelatin or a mixture thereof, concentrating and drying the resultant blend. Thus, the CSF is entrapped in the carrier. The resultant material is then suitably processed depending on the purpose. For example, the material is pulverized to an injectable particle diameter while cooling with dry ice, etc., and suspended in a solvent for injection to afford a sustained release suspension type injection. Alternatively, the material is molded into a spherical, cylindrical shape, etc., and can be administered by a method of in vivo imbedding, intracoelemic inserting, etc. Multipotential SCF, granulocytic SCF, etc., are cited as the CSF.

Data supplied from the esp@cenet database - 12